Literature DB >> 17917504

Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension.

Samira Ubaid-Girioli1, Sílvia Elaine Ferreira-Melo, Leoní Adriana Souza, Eduardo Arantes Nogueira, Juan Carlos Yugar-Toledo, Antonio Coca, Heitor Moreno.   

Abstract

Renin-angiotensin-aldosterone system (RAAS) hyperactivity is implicated in the development of hypertension and progressive damage in target organs. Chronic inhibition of the RAAS or use of thiazide-type diuretics may trigger an aldoster-one escape. The aim of this study was to assess this phenomenon in hypertensive patients treated with thiazide-type diuretics (hydrochlorothiazide [HCTZ]) or single or double blockade of the RAAS (irbesartan [IRBE], quinapril [QUIN], and IRBE+QUIN). Blood pressure levels were obtained by 24-hour ambulatory blood pressure monitoring. Plasma renin activity and aldosterone levels were determined by immunoradiometric assay. Blood pressure level was normalized in the 4 treatment groups; the HCTZ and IRBE+QUIN groups showed an increased plasma aldosterone level after 12 weeks (9.1+/-2.2 to 14.1+/-1.4 and 6.9+/-1.9 to 12.9+/-2.3 ng/dL, respectively; P<.05), whereas plasma renin activity was increased only in the HCTZ group (0.9+/-0.2-1.7+/-0.2 ng/mL/h; P<.05). The increase in plasma aldosterone level after 12 weeks of HCTZ and IRBE+QUIN therapy suggests early aldosterone escape.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917504      PMCID: PMC8109961          DOI: 10.1111/j.1751-7176.2007.tb00091.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  21 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  The pathophysiology of aldosterone in the cardiovascular system.

Authors:  Ricardo Rocha; John W Funder
Journal:  Ann N Y Acad Sci       Date:  2002-09       Impact factor: 5.691

3.  Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.

Authors:  G S Stergiou; I I Skeva; N M Baibas; L G Roussias; C B Kalkana; A D Achimastos; T D Mountokalakis
Journal:  J Cardiovasc Pharmacol       Date:  2000-06       Impact factor: 3.105

Review 4.  Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.

Authors:  Michel Azizi; Joël Ménard
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

5.  Additive effects of losartan and enalapril on blood pressure and plasma active renin.

Authors:  M Azizi; T T Guyene; G Chatellier; M Wargon; J Ménard
Journal:  Hypertension       Date:  1997-02       Impact factor: 10.190

Review 6.  Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.

Authors:  Atsuhisa Sato; Takao Saruta; John W Funder
Journal:  Hypertens Res       Date:  2006-04       Impact factor: 3.872

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 8.  Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.

Authors:  George S Stergiou; Irini I Skeva
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 9.  Review of aldosterone- and angiotensin II-induced target organ damage and prevention.

Authors:  Allan D Struthers; Thomas M MacDonald
Journal:  Cardiovasc Res       Date:  2004-03-01       Impact factor: 10.787

Review 10.  The new biology of aldosterone.

Authors:  John M C Connell; Eleanor Davies
Journal:  J Endocrinol       Date:  2005-07       Impact factor: 4.286

View more
  6 in total

1.  Deregulation of adipokines related to target organ damage on resistant hypertension.

Authors:  A R Sabbatini; A P Faria; N R Barbaro; W M Gordo; R G P Modolo; C Pinho; V Fontana; H Moreno
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

Review 2.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

Review 3.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

Review 4.  Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.

Authors:  Harikrishna Makani; Sripal Bangalore; Azhar Supariwala; Jorge Romero; Edgar Argulian; Franz H Messerli
Journal:  Eur Heart J       Date:  2013-08-21       Impact factor: 29.983

5.  Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.

Authors:  Xiaotong Song; Yue Zhao; Shijun Wang; Yuan Wang; Qian Chen; Haijun Zhao; Hua Wang; Sheng Tian; Huayun Yu; Zhichun Wu
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

6.  Aldosterone excess or escape: Treating resistant hypertension.

Authors:  Samira Ubaid-Girioli; Leoní Adriana de Souza; Juan Carlos Yugar-Toledo; Luiz Cláudio Martins; Sílvia Ferreira-Melo; Otávio Rizzi Coelho; Cristina Sierra; Antonio Coca; Eduardo Pimenta; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-05       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.